AstraZeneca Pharma India (NSE:ASTRAZEN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
AstraZeneca Pharma India EBITDA Margin % Related Terms
AstraZeneca Pharma India EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca Pharma India (NSE:ASTRAZEN) has a EBITDA Margin % of 11.37% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AstraZeneca Pharma India and its competitors. This is near median its historical median of 12.54. Over the past decade, AstraZeneca Pharma India's EBITDA Margin % has ranged from 8.36 to 18.30. According to the industry distribution chart, AstraZeneca Pharma India ranks #474 out of 955 companies in the Drug Manufacturers industry, placing it in the top 49.6%.
Is AstraZeneca Pharma India's EBITDA Margin % too high?
AstraZeneca Pharma India's current EBITDA Margin % of 11.37% is near median its 10-year median of 12.54. Over the past 10 years, this metric has ranged from a low of 8.36 to a high of 18.30. The Drug Manufacturers industry median EBITDA Margin % is 12.39. AstraZeneca Pharma India's value of 11.37% is 8.2% below this industry median. Based on the distribution chart, AstraZeneca Pharma India ranks #474 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, AstraZeneca Pharma India has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #474 out of 955 companies for EBITDA Margin %. This puts AstraZeneca Pharma India in the upper half of its industry. The industry median EBITDA Margin % is 12.39. AstraZeneca Pharma India's value of 11.37% is 8.2% below this benchmark. Historically, AstraZeneca Pharma India's own EBITDA Margin % has ranged from 8.36 to 18.30 over the past decade. While the company's 10-year median is 12.54 vs. the industry median of 12.39, AstraZeneca Pharma India has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca Pharma India's current EBITDA Margin % of 11.37% is 8.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AstraZeneca Pharma India and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current EBITDA Margin % is 11.37%, which is near median its own 10-year median of 12.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹10,868.58, compared to a current price of ₹8,391.00 — trading 22.8% below its estimated fair value. The current EBITDA Margin % is 11.37%, which is near median its 10-year median of 12.54 and 8.2% below the Drug Manufacturers industry median of 12.39. AstraZeneca Pharma India's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current EBITDA Margin % is 11.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹8,391.00 is trading 22.8% below its estimated GF Value™ of ₹10,868.58.
GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.
Key valuation signals for NSE:ASTRAZEN:
EBITDA Margin %: 11.37% (near median its 10-year median of 12.54)
GF Value™: ₹10,868.58 vs. price of ₹8,391.00 (22.8% below fair value)
Industry Position: 8.2% below the Drug Manufacturers median (#474 of 955)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
92GF Score
Get the complete analysis for NSE:ASTRAZEN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
